Literature DB >> 32009207

Perspective: a critical assessment of PI-RADS 2.1.

T Ullrich1,2, L Schimmöller3.   

Abstract

PURPOSE: In this article we take a critical look at the key changes of the newest edition of the Prostate Imaging Reporting and Data System (PI-RADS) version 2.1 (v2.1) and indicate future directions for further development of the system.
CONCLUSION: PI-RADS v2.1 addresses some of the shortcomings of its widely embraced precursor version 2, largely to simplify interpretation and improve interobserver agreement without changing the fundamental acquisition and scoring guidelines. Biparametric MRI is acknowledged in the newest version, but multiparametric MRI including dynamic contrast-enhanced imaging is still recommended for most scenarios. Management recommendations and guidance on evaluation of follow-up MRI's are still not included in the system.

Keywords:  Guidelines; MRI; PI-RADS; Prostate biopsy; Prostate cancer; Prostate imaging reporting and data system

Mesh:

Year:  2020        PMID: 32009207     DOI: 10.1007/s00261-020-02424-7

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  28 in total

Review 1.  Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis.

Authors:  Sungmin Woo; Chong Hyun Suh; Sang Youn Kim; Jeong Yeon Cho; Seung Hyup Kim
Journal:  Eur Urol       Date:  2017-02-11       Impact factor: 20.096

2.  Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists.

Authors:  Andrew B Rosenkrantz; Luke A Ginocchio; Daniel Cornfeld; Adam T Froemming; Rajan T Gupta; Baris Turkbey; Antonio C Westphalen; James S Babb; Daniel J Margolis
Journal:  Radiology       Date:  2016-04-01       Impact factor: 11.105

3.  Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate.

Authors:  Tim Ullrich; Michael Quentin; Christian Arsov; Anna Katharina Schmaltz; Alexander Tschischka; Nina Laqua; Andreas Hiester; Dirk Blondin; Robert Rabenalt; Peter Albers; Gerald Antoch; Lars Schimmöller
Journal:  J Urol       Date:  2017-09-20       Impact factor: 7.450

Review 4.  Genomic Markers in Prostate Cancer Decision Making.

Authors:  Vito Cucchiara; Matthew R Cooperberg; Marc Dall'Era; Daniel W Lin; Francesco Montorsi; Jack A Schalken; Christopher P Evans
Journal:  Eur Urol       Date:  2017-11-10       Impact factor: 20.096

5.  A Comparison of Radiologists' and Urologists' Opinions Regarding Prostate MRI Reporting: Results From a Survey of Specialty Societies.

Authors:  Benjamin Spilseth; Sangeet Ghai; Nayana U Patel; Samir S Taneja; Daniel J Margolis; Andrew B Rosenkrantz
Journal:  AJR Am J Roentgenol       Date:  2017-10-24       Impact factor: 3.959

6.  Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up.

Authors:  Soroush Rais-Bahrami; Barış Türkbey; Ardeshir R Rastinehad; Annerleim Walton-Diaz; Anthony N Hoang; M Minhaj Siddiqui; Lambros Stamatakis; Hong Truong; Jeffrey W Nix; Srinivas Vourganti; Kinzya B Grant; Maria J Merino; Peter L Choyke; Peter A Pinto
Journal:  Diagn Interv Radiol       Date:  2014 Jul-Aug       Impact factor: 2.630

7.  Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.

Authors:  Satoshi Washino; Tomohisa Okochi; Kimitoshi Saito; Tsuzumi Konishi; Masaru Hirai; Yutaka Kobayashi; Tomoaki Miyagawa
Journal:  BJU Int       Date:  2016-04-01       Impact factor: 5.588

8.  mp-MRI Prostate Characterised PIRADS 3 Lesions are Associated with a Low Risk of Clinically Significant Prostate Cancer - A Retrospective Review of 92 Biopsied PIRADS 3 Lesions.

Authors:  Heath Liddell; Rajeev Jyoti; Hodo Z Haxhimolla
Journal:  Curr Urol       Date:  2015-07-10

9.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

Review 10.  MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?

Authors:  Ivo G Schoots
Journal:  Transl Androl Urol       Date:  2018-02
View more
  3 in total

1.  Comparison of prostate imaging reporting and data system v2.1 and 2 in transition and peripheral zones: evaluation of interreader agreement and diagnostic performance in detecting clinically significant prostate cancer.

Authors:  Yasuyo Urase; Yoshiko Ueno; Tsutomu Tamada; Keitaro Sofue; Satoru Takahashi; Nobuyuki Hinata; Kenichi Harada; Masato Fujisawa; Takamichi Murakami
Journal:  Br J Radiol       Date:  2021-07-08       Impact factor: 3.039

2.  Evaluation of a multiparametric MRI radiomic-based approach for stratification of equivocal PI-RADS 3 and upgraded PI-RADS 4 prostatic lesions.

Authors:  Valentina Brancato; Marco Aiello; Luca Basso; Serena Monti; Luigi Palumbo; Giuseppe Di Costanzo; Marco Salvatore; Alfonso Ragozzino; Carlo Cavaliere
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

3.  Diagnostic Ability of Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Prostate Cancer and Clinically Significant Prostate Cancer in Equivocal Lesions: A Systematic Review and Meta-Analysis.

Authors:  Jing Zeng; Qingqing Cheng; Dong Zhang; Meng Fan; Changzheng Shi; Liangping Luo
Journal:  Front Oncol       Date:  2021-02-19       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.